GO
Loading...

Medicine

More

  • July 11- Two members of the U.S. Senate Finance Committee, including Chairman Ron Wyden, on Friday asked Gilead Sciences Inc to defend the more than $80,000 cost of its breakthrough new treatment for hepatitis C, citing the expense to federal healthcare programs.

  • Sanofi dengue vaccine promising but questions remain Thursday, 10 Jul 2014 | 7:01 PM ET

    PARIS, July 11- The first vaccine against dengue fever, from France's Sanofi, provided moderate protection in a large clinical study, but questions remain as to how well it can help fight the world's fastest-growing tropical disease.

  • The doctor will see you now     Thursday, 10 Jul 2014 | 2:00 PM ET

    In a continuing effort to cut costs and make medical care more convenient, insurers and employers are starting to embrace telemedicine - seeing a doctor online. Bertha Coombs looks at how telemedicine works, and how widespread the practice could become.

  • Blazing the pot industry trail     Wednesday, 9 Jul 2014 | 10:21 AM ET

    Former Governor Gary Johnson, (R-N.M.), discusses the medical marijuana movement, and his high hopes for expanding the pot industry. Johnson also explains the medical benefits of oil-based cannabis.

  • July 9- Celgene Corp said a drug being tested to treat a type of arthritis that affects the spine failed to meet the main goal in a late-stage trial, sending the company's shares down 3 percent premarket. Celgene said it would continue the study unchanged based on a recommendation by an independent data monitoring committee.

  • NEW YORK, July 8- That obesity can cut life short by causing strokes and other illnesses comes as no surprise, but a study reported on Tuesday quantifies the toll: The most extreme cases cut a person's lifespan more than cigarettes. The analysis, published in the journal PLOS Medicine, is the largest-ever study of the effect of extreme obesity on mortality.

  • July 8- Anacor Pharmaceutical Inc said the U.S. Food and Drug Administration approved its treatment for a fungal infection of the toenail. The topical solution, Kerydin, is expected to be launched as early as the end of the quarter in the United States, the company said on Tuesday.

  • Washington weed on sale     Tuesday, 8 Jul 2014 | 11:13 AM ET

    Bob Leeds, Sea of Green Farms, is a licensed marijuana grower in the state of Washington. Leeds discusses his upstart progression and says he has invested about $2 million in the process to date.

  • Legal pot in Washington     Tuesday, 8 Jul 2014 | 11:07 AM ET

    Teresa Yuan, King TV, reports from one of the first legal marijuana shops in the state of Washington.

  • In preparatory documents posted on the agency's website on Tuesday, FDA reviewers said laparoscopic power morcellator devices, which are used to treat uterine fibroids, allow for less invasive surgeries, shorter recovery time and fewer wound site infections.

  • July 8- German drugmaker Boehringer Ingelheim said its experimental blood cancer drug met its main goal in a mid-stage trial and improved overall survival rate among patients.

  • FDA approves Anacor Pharma's drug for nail infection Tuesday, 8 Jul 2014 | 8:49 AM ET

    July 8- Anacor Pharmaceutical Inc said the U.S. Food and Drug Administration approved its treatment for a fungal infection of the nail, sending the drug developer's shares up about 9 percent in premarket trade. Onychomycosis is a progressive, recurring fungal infection of the nail and nail bed and affects about 35 million people in the United States, Anacor said.

  • Boehringer cancer drug effective in mid-stage trial Tuesday, 8 Jul 2014 | 8:18 AM ET

    July 8- German drugmaker Boehringer Ingelheim said its experimental blood cancer drug met its main goal in a mid-stage trial. Data showed the cancer was not found in 31 percent of the patients treated with the drug volasertib along with a chemotherapy agent versus 13.3 percent of patients who were administered the chemotherapy alone.

  • Protect yourself from fake medicine     Monday, 7 Jul 2014 | 1:55 PM ET

    CNBC's Scott Cohn follows up on his investigation into the high cost of prescription drugs and reports how consumers can protect themselves from getting fake medicine.

  • FDA approves Spectrum Pharma's blood cancer drug Thursday, 3 Jul 2014 | 11:19 AM ET

    July 3- Spectrum Pharmaceuticals Inc's drug for the treatment of an aggressive form of blood cancer was granted an accelerated approval by the U.S. Food and Drug Administration on Thursday. Beleodaq is the third drug to win approval for the condition since 2009, the other two being Spectrum's injection Folotyn and Celgene Corp's drug Istodax.

  • NEW YORK, July 2- Jamie Dimon, chairman and chief executive of JPMorgan Chase& Co, plans to be out of the office for at least half of his planned two-month course of radiation treatment and chemotherapy for throat cancer, a spokesman said on Wednesday.

  • July 2- Drug developer Bind Therapeutics said it ended a partnership with Amgen Inc to develop targeted cancer therapy due to unsatisfactory results.

  • NEW YORK, July 1- JPMorgan Chase& Co Chief Executive Jamie Dimon said he has been diagnosed with throat cancer but that the ailment is curable and he plans to remain actively involved in the business and continue to run the largest U.S. bank.

  • NEW YORK, July 1- JPMorgan Chase& Co Chief Executive Jamie Dimon told the bank's employees and shareholders on Tuesday that he has been diagnosed with curable throat cancer. Dimon has notified JPMorgan's board. Dimon became chairman of the board on Dec. 31, 2006, and has been CEO and president since Dec. 31, 2005.

  • NEW YORK, July 1- JPMorgan Chase& Co Chief Executive Officer Jamie Dimon has told the bank's employees and shareholders he has been diagnosed with curable throat cancer, Dow Jones reported on Tuesday. Dimon has notified JPMorgan's board, Dow Jones added. A JPMorgan spokeswoman did not immediately respond to a request for comment.